Jeffrey Elliott Appointed to Quanterix’s Board of Directors

Rhea-AI Summary

Quanterix (NASDAQ: QTRX) has appointed Jeffrey Elliott to its Board of Directors. Elliott brings 20 years of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp. as CFO and COO. His expertise includes finance, strategy, and business development, with a track record of scaling operations and achieving high revenue growth. Elliott's appointment comes at a important time as Quanterix builds infrastructure for Alzheimer's Disease testing.

Elliott's background includes roles as a senior equity research analyst covering health care companies and a CFA® charterholder. He holds a B.S. in Business Administration from the University of Illinois and an MBA from the University of Chicago. Quanterix CEO Masoud Toloue and Board Chairman Martin Madaus expressed enthusiasm about Elliott's addition to the board, citing his valuable experience in scaling operations and financial expertise.

Positive

• Appointment of Jeffrey Elliott with 20 years of senior leadership experience in medical diagnostics
• Elliott's track record of scaling operations and achieving high revenue growth at Exact Sciences
• Elliott's expertise in finance, strategy, and business development
• Timing of appointment aligns with Quanterix's focus on building Alzheimer's Disease testing infrastructure

Negative

• None.

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors.

Mr. Elliott brings two decades of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp., where he served as chief financial officer from November 2016 to May 2024 and chief operating officer from April 2021 to May 2023. While at Exact Sciences, he was responsible for finance, strategy and business development, helping to effectively scale the business, achieving high revenue growth during his tenure, and overseeing numerous acquisitions and venture investments.

Prior to joining Exact Sciences, Mr. Elliott was a senior equity research analyst at Robert W. Baird & Co. where he covered health care companies, including companies in the diagnostics and life science tools industry. He brings to Quanterix a breadth of business strategy experience within the life sciences industry.

Mr. Elliott earned a Bachelor of Science in business administration from the University of Illinois at Urbana-Champaign and an M.B.A. from the University of Chicago Booth School of Business. Mr. Elliott is a CFA^® charterholder.

“We’re pleased to welcome Jeff to our board of directors at an exciting time for the company. As Quanterix actively builds the infrastructure for Alzheimer’s Disease testing to ensure access to early diagnosis, Jeff's experience in scaling Exact Sciences’ operations and financial experience will be invaluable,” said Masoud Toloue, CEO of Quanterix.

“Jeff is a wonderful addition to our Board, and we look forward to leveraging his expertise in the industry as Quanterix continues to grow,” said Martin Madaus, Chairman of the Board.

“It is a pivotal time in life sciences and diagnostics, and I’m thrilled to join the Quanterix board amid great innovation and opportunity,” said Mr. Elliott. “The mission to scale Quanterix’s Simoa technology is bold and ambitious, and I am excited to apply my experience to help the company achieve this goal and support continued innovation.”

To learn more about Quanterix’s Simoa^® technology, visit: https://www.quanterix.com/simoa-technology/.

About Quanterix

From discovery to diagnostics, Quanterix’s ultra-sensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa^® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240819478224/en/

Quanterix Media:

Maya Nimnicht, PAN Communications

(510) 334-6273

pan.quanterix@pancomm.com

Investor Relations:

Quanterix

Francis Pruell

(508) 789-1725

ir@quanterix.com

Source: Quanterix Corporation

FAQ

Who is the new Board of Directors member for Quanterix (QTRX)?

Jeffrey Elliott has been appointed to Quanterix's (QTRX) Board of Directors. He brings 20 years of senior leadership experience in the medical diagnostics industry, including roles as CFO and COO at Exact Sciences Corp.

What is Quanterix (QTRX) focusing on in terms of product development?

Quanterix (QTRX) is actively building the infrastructure for Alzheimer's Disease testing to ensure access to early diagnosis. They are working to scale their Simoa technology for this purpose.

What is Jeffrey Elliott's background before joining Quanterix's (QTRX) board?

Before joining Quanterix's (QTRX) board, Jeffrey Elliott spent 8 years at Exact Sciences Corp. as CFO and COO. He was also a senior equity research analyst at Robert W. Baird & Co., covering health care companies, including those in diagnostics and life science tools.

How does Quanterix (QTRX) expect to benefit from Jeffrey Elliott's appointment?

Quanterix (QTRX) expects to benefit from Jeffrey Elliott's experience in scaling operations, financial expertise, and industry knowledge. His skills are seen as valuable for the company's growth and efforts to scale its Simoa technology, particularly in Alzheimer's Disease testing.